Could a single injection fix your aching back?

NCT ID NCT06144970

Not yet recruiting Disease control Sponsor: Kolon TissueGene, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new cell-based injection called TG-C for people with long-term lower back pain due to degenerative disc disease. 24 adults aged 22 to 70 will receive either a high, mid, or low dose of TG-C injected into the spinal disc, or a sham (fake) injection. The main goal is to check safety over 24 months, with pain levels also tracked.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TG-C (a mixture of cells injected into the spinal disc)
What this could lead to: If safe and effective, this could point toward a non-surgical treatment for chronic back pain caused by worn-out discs.
What could go wrong: This is a very early Phase 1 trial with only 24 people, so it is primarily checking safety, not whether it works. The treatment involves injecting cells into the spine, which carries risks like infection or nerve damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEGENERATIVE DISC DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

intervertebral disk degenerative disorder lumbar disk degenerative disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEGENERATIVE DISC DISEASE

More trials for these conditions

Other studies related to the condition(s) this trial covers.